Richard Scott Struthers - 12 Oct 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
12 Oct 2022
Transactions value $
$21,201
Form type
4
Filing time
14 Oct 2022, 16:55:04 UTC
Previous filing
15 Apr 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $21.2K +11.1K +19.34% $1.91* 68.5K 12 Oct 2022 Direct
holding CRNX Common Stock 731K 12 Oct 2022 By Family Trust 1
holding CRNX Common Stock 1K 12 Oct 2022 By Spouse
holding CRNX Common Stock 90K 12 Oct 2022 By Family Trust 2
holding CRNX Common Stock 90K 12 Oct 2022 By Family Trust 3
holding CRNX Common Stock 90K 12 Oct 2022 By Family Trust 4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Incentive stock option (Right to Buy) Options Exercise $0 -11.1K -6.44% $0.00 161K 12 Oct 2022 Common Stock 11.1K $1.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.